New York, NY
Axiom Accelerated Patient Recruitment (Axiom), is introducing innovative new text messaging (SMS) services.
“Mobile device outreach is the future of patient recruitment, due to the growth and convenience of this rapid-response medium,” said Jeff Clausing, Axiom Vice President.
According to NielsenMobile, a service of the Nielsen Company, a typical US mobile subscriber sends or receives an average of 357 text messages per month - 4,284 messages per year. Additionally, roughly 73% of mobile users already have a paid text messaging plan – a number that’s grown by 250% annually for the past two years.
Axiom is taking advantage of this growing trend by implementing text messaging services as part of its comprehensive patient recruitment and retention programs for clinical research studies.
“Clinical studies are an important way to advance research. In an era when healthcare is one of the nation’s leading topics of conversation, we believe clinical studies should be accessible to as many people as possible,” continued Julie Oimoen, Project Manager at Axiom. “We can best accomplish this by allowing potential participants to respond by using the medium with which they’re most comfortable. For many candidates in today’s world, that means text messaging.”
Axiom is able to identify pre-qualified audiences for numerous ailments and diseases ranging from asthma to adolescent schizophrenia. Text messages can be used to directly communicate with these pre-qualified audiences to gauge interest in participating in a clinical study that may help minimize symptoms or treat the disease. These services can also retain participants through support services like appointment reminders and treatment instructions. Text messaging provides a convenient, direct way to get in touch with pre-qualified potential patients quickly and efficiently.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.